Region:Asia
Author(s):Rebecca
Product Code:KRAC3896
Pages:80
Published On:October 2025
By Type:The market is segmented into various types of liquid embolic agents, including N-butyl cyanoacrylate (NBCA), ethylene vinyl alcohol copolymer (EVOH), polyvinyl alcohol (PVA) particles, non-adhesive liquid embolics, and others. Among these, N-butyl cyanoacrylate (NBCA) and ethylene vinyl alcohol copolymer (EVOH) are the most widely used due to their effectiveness in various embolization procedures and established safety profiles. The increasing adoption of these agents in clinical settings is driven by their versatility and the growing number of interventional radiology procedures. Cyanoacrylates, including NBCA, are experiencing the fastest growth globally, which may reflect similar trends in Vietnam as advanced products become more accessible .
By Application:The applications of liquid embolic agents include arteriovenous malformations (AVMs), tumor embolization, aneurysm treatment, gastrointestinal bleeding, uterine fibroid embolization, and others. Tumor embolization is the leading application segment, driven by the rising incidence of various cancers and the increasing preference for minimally invasive treatment options. The effectiveness of liquid embolic agents in targeting tumors has made them a preferred choice among healthcare providers. Globally, AVMs represent a significant application segment, but in Vietnam, tumor embolization may lead due to the high burden of liver and other cancers requiring interventional therapy .
The Vietnam Liquid Embolic Agent Market is characterized by a dynamic mix of regional and international players. Leading participants such as Medtronic, Boston Scientific Corporation, Johnson & Johnson (DePuy Synthes/Codman Neuro), Terumo Corporation, Cook Medical, Merit Medical Systems, Stryker Corporation, AngioDynamics, Penumbra, Inc., Asahi Intecc Co., Ltd., B. Braun Melsungen AG, Abbott Laboratories, Hologic, Inc., GE HealthCare, Siemens Healthineers, Balt Group, MicroVention, Inc. (Terumo Group), GEM Srl, BlackSwan Vascular, Inc., INVAMED contribute to innovation, geographic expansion, and service delivery in this space.
The future of the Vietnam liquid embolic agent market appears promising, driven by increasing healthcare investments and a growing focus on advanced medical technologies. As the government continues to enhance healthcare infrastructure, the accessibility of liquid embolic agents is expected to improve. Additionally, the rising demand for personalized medicine and targeted therapies will likely create new avenues for growth, encouraging innovation and collaboration among industry stakeholders to meet evolving patient needs.
| Segment | Sub-Segments |
|---|---|
| By Type | N-butyl cyanoacrylate (NBCA) Ethylene vinyl alcohol copolymer (EVOH, e.g., Onyx) Polyvinyl alcohol (PVA) particles Non-adhesive liquid embolics (e.g., PHIL, Squid) Others |
| By Application | Arteriovenous malformations (AVMs) Tumor embolization (e.g., hepatocellular carcinoma, neuroendocrine tumors) Aneurysm treatment Gastrointestinal bleeding Uterine fibroid embolization Others |
| By End-User | Hospitals Ambulatory surgical centers Specialty clinics (e.g., interventional radiology centers) Academic & research institutes Others |
| By Distribution Channel | Direct sales Distributors/wholesalers Online sales Others |
| By Region | Northern Vietnam Southern Vietnam Central Vietnam Others |
| By Price Range | Low Medium High |
| By Policy Support | Subsidies Tax exemptions Grants for research Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Interventional Radiology Practices | 50 | Interventional Radiologists, Medical Directors |
| Hospital Procurement Departments | 45 | Procurement Managers, Supply Chain Officers |
| Clinical Usage in Oncology | 40 | Oncologists, Clinical Researchers |
| Vascular Surgery Units | 45 | Vascular Surgeons, Surgical Coordinators |
| Medical Device Distributors | 50 | Sales Managers, Product Specialists |
The Vietnam Liquid Embolic Agent Market is valued at approximately USD 12 million, driven by the increasing prevalence of vascular diseases and advancements in medical technology, alongside a growing number of interventional procedures.
What makes us stand out is that our consultants follow Robust, Refine and Result (RRR) methodology. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents' facts and opinions, and Result for presenting data with story.
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.
